治疗医院对肝细胞癌诊疗结局的影响
基于美国国家癌症数据库2004—2012年50,381例18—70岁肝细胞癌患者的回顾性队列研究,按医院提供的治疗水平分为四类,评估医院类型与总死亡风险的关系。结果显示,提供全套肝细胞癌治疗的IV类医院五年生存率最高,死亡风险随医院治疗水平呈剂量-反应关系降低,但三分之一的患者未在这类医院接受治疗。
要点
- IV类医院(可移植)收治65%患者,III类26%,II类3%,I类6%。
- 未治疗者五年生存率IV类13.1% vs I类5.7%、II类7.0%、III类7.4%(log-rank P<0.001)。
- 死亡风险随医院类型呈剂量-反应关系:以I类为参照,II类HR 0.81(95%CI 0.73-0.90),III类HR 0.67(0.62-0.72),IV类HR 0.43(0.39-0.47)。
核心结论
- 在提供全套肝细胞癌治疗的医院接受诊疗与死亡风险降低相关,但三分之一的患者未在这类医院接受治疗。
- 这些数据可为肝细胞癌诊疗区域化的卫生政策举措提供价值参考。
研究设计与样本
- 回顾性队列研究,纳入美国国家癌症数据库2004—2012年18—70岁肝细胞癌患者50,381例。
- 按医院提供的治疗水平分为四类:I类为非手术,II类为消融,III类为切除,IV类为移植。
- 采用多变量Cox共享脆弱模型评估总死亡风险与医院类型的关联。
主要发现
- 50,381例患者中,65%在IV类医院接受诊疗,26%在III类,3%在II类,6%在I类。
- 未治疗者五年生存率:IV类13.1% vs I类5.7%、II类7.0%、III类7.4%(log-rank P<0.001)。
- 化疗和/或放疗者五年生存率:IV类18.1% vs I类3.6%、II类4.6%、III类7.7%(log-rank P<0.001)。
- 消融者五年生存率:IV类33.3% vs II类13.6%、III类23.6%(log-rank P<0.001)。
- 切除者五年生存率:IV类48.4% vs III类39.1%(log-rank P<0.001)。
临床怎么用
- 原文结论指出,在提供全套肝细胞癌治疗的医院接受诊疗与死亡风险降低相关,但三分之一患者未在这类医院接受治疗。
- 原文指出这些数据可为肝细胞癌诊疗区域化的卫生政策举措提供价值参考。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multidisciplinary hepatocellular carcinoma (HCC) treatment is associated with optimal outcomes. There are few data analyzing the impact of treating hospitals' therapeutic offerings on survival. We performed a retrospective cohort study of patients aged 18-70 years with HCC in the National Cancer Database (2004-2012). Hospitals were categorized based on the level of treatment offered (Type I-nonsurgical; Type II-ablation; Type III-resection; Type IV-transplant). Associations between overall risk of death and hospital type were evaluated with multivariable Cox shared frailty modeling. Among 50,381 patients, 65% received care in Type IV hospitals, 26% in Type III, 3% in Type II, and 6% in Type I. Overall 5-year survival across modalities was highest at Type IV hospitals (untreated: Type IV-13.1% versus Type I-5.7%, Type II-7.0%, Type III-7.4% [log-rank, P < 0.001]; chemotherapy and/or radiation: Type IV-18.1% versus Type I-3.6%, Type II-4.6%, Type III-7.7% [log-rank, P < 0.001]; ablation: Type IV-33.3% versus Type II-13.6%, Type III-23.6% [log-rank, P < 0.001]; resection: Type IV-48.4% versus Type III-39.1% [log-rank, P < 0.001]). Risk of death demonstrated a dose-response relationship with the hospital type-Type I (ref); Type II (hazard ratio [HR] 0.81, 95% confidence interval [0.73-0.90]); Type III (HR 0.67 [0.62-0.72]); Type IV hospitals (HR 0.43 [0.39-0.47]). Conclusion: Although care at hospitals offering the full complement of HCC treatments is associated with decreased risk of death, one third of patients are not treated at these hospitals. These data can inform the value of health policy initiatives regarding regionalization of HCC care.
引用
- Cotton RT, Tran Cao HS, Rana AA, et al. Impact of the Treating Hospital on Care Outcomes for Hepatocellular Carcinoma. Hepatology. 2018. PMID: 30070392. doi:10.1002/hep.30128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。